Month: September 2026

Tórshavn, Faroe Islands, 2026-09-30 (GLOBE NEWSWIRE) — Today P/F Atlantic Petroleum (Nasdaq Copenhagen: ATLA DKK) has submitted an Application for an Exploration and Production Licence in the Faroe Islands under the Open Door Licensing Regime.

Atlantic Petroleum has today, through an associated company currently under formation, submitted an application to Jarðfeingi for an exploration and production licence in the Faroe Islands.

Atlantic Petroleum will hold a 40% carried equity interest in the company applying for the licence.

Following submission of the application under the Open Door Licensing Regime, a licence may be granted following a public notice announcing that an application has been received by Jarðfeingi.

Other interested parties may apply for the same area, or parts thereof, subject to an application deadline of at least ninety days from the date of the public notice.

Further Details:

Further details can be obtained from Mark T. Højgaard, (markh@petroleum.fo). This announcement will be available, together with other information about Atlantic Petroleum, on the Company’s website: www.petroleum.fo.

Announcement no.15/2026

Issued 30-09-2026

P/F Atlantic Petroleum
P.O. Box 1228
FO-110 Tórshavn
Faroe Islands

Website: www.petroleum.fo

ORINDA, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — MacKenzie Realty Capital, Inc. (Nasdaq: MKZR) (“MacKenzie” or the “Company”) today announced its financial results for the year ended June 30, 2026 and announced that its Board has temporarily suspended the Preferred Share Repurchase Program while it explores strategic transactions such as reverse takeovers. 

Key Financial Highlights:
Operating Results for the Year Ended June 30, 2026:

• Net revenues for year ended June 30, 2026, were $20.01 million, a decrease of 9% from $22.06 million in the same period of 2025.
• Net operating loss was $15.61 million, a decrease of 33% as compared to a net operating loss of $23.46 million in the same period of 2025.
• Net loss was $14.13 million, a decrease of 41% compared to a $23.97 million loss in the same period of 2025.

Robert Dixon, CEO and President of MacKenzie Realty Capital, stated, “While net revenues declined 9% compared to the prior year (primarily due to approximately $3.0 million of lease termination income recognized in the 2025 period), the annual results were in line with our internal expectations, and the Company achieved meaningful reductions in net operating loss and net loss. We remain focused on executing our growth initiatives while maintaining financial discipline which we believe will deliver sustained value creation over the long term.”

Board Temporarily Suspends Preferred Share Repurchase Program

To enable the Company to better react to any strategic alternative that may be brought to it by its financial advisor, Maxim Group LLC (“Maxim”), the Board has determined to temporarily suspend the Preferred Share Repurchase Program. The Company’s issuance of common stock in exchange for preferred shares has resulted in additional selling pressure on the Company’s common stock, which the Board believes would make the negotiation of any potential strategic transaction more difficult. The Company continues to review strategic alternatives brought to it by Maxim, and the Board expects to reassess the Preferred Share Repurchase Program in due course. There can be no assurance that the Company will enter into any strategic transaction as a result of these efforts, and the Company undertakes no obligation to provide further updates on its strategic review except as required by applicable law.

About MacKenzie Realty Capital, Inc. 
MacKenzie, founded in 2013, is a West Coast-focused REIT that intends to invest at least 80% of its total assets in real property, and up to a maximum of 20% of its total assets in illiquid real estate securities.  We intend for the real property portfolio to be approximately 50% multifamily and 50% boutique class A office. The current portfolio includes interests in 5 multifamily properties and 8 office properties plus 1 multifamily development.

For more information, please contact MacKenzie at (800) 854-8357. Please visit our website at: http://www.mackenzierealty.com

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, our ability to remain financially healthy, our expected future growth prospects, , and our ability to successfully complete a transaction resulting from a strategic alternative that may be brought to us by our financial advisor, Maxim. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory,” “focus,” “work to,” “attempt,” “pursue,” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. For a further discussion of factors that could cause our future results, performance, or transactions to differ significantly from those expressed in any forward-looking statement, please see the section titled “Risk Factors” in annual reports on Form 10-K and quarterly reports on Form 10-Q that we file with the Securities and Exchange Commission from time to time. 

GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company.

The option award has an exercise price of $4.22 per share, the closing price of the Company’s common stock on September 25, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the recipient’s continued service through each applicable vesting date.

The above grant was approved by the Company’s Compensation Committee and was made as an inducement material to the employee entering into employment with Adial. The grant was made outside of the Company’s equity incentive plans and in reliance on the employment inducement exception to shareholder approval provided under Nasdaq Listing Rule 5635(c)(4), which requires public announcement of inducement awards.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has historically focused on the development of treatments for addictions and related disorders. In June 2026, the Company acquired Azora Therapeutics, a biopharmaceutical company focused on treating autoimmune diseases, including ulcerative colitis (“UC”). Following the acquisition of Azora, the Company’s focus has shifted to the treatment of serious inflammatory diseases, and its lead program is AT177, which is being studied for the treatment of UC. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. Its active ingredient is a prodrug of indirubin, the most potent AhR agonist within indigo naturalis, a botanical extract with best-in-category clinical efficacy in UC. In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic exposure. AT177 is currently in IND-enabling studies, with an investigational new drug (“IND”) filing planned for the first half of 2027, initiation of a Phase 1a single- and multiple-ascending-dose (“SAD/MAD”) clinical trial planned to commence in the second half of 2027, followed by a Phase 1b proof-of-concept study in UC patients. Additional information is available at www.adial.com.

Cautionary Note Regarding Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include, but are not limited to, statements regarding the vesting of the inducement awards and IND filing planned for the first half of 2027, initiation of a Phase 1a single- and multiple-ascending-dose clinical trial planned to commence in the second half of 2027, followed by a Phase 1b proof-of-concept study in UC patients. Any forward-looking statements included herein reflect the Company’s current views, and they involve certain risks and uncertainties, including, among others, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to develop strategic partnership opportunities and maintain collaborations; the Company’s ability to obtain or maintain the capital or grants necessary to fund its research and development activities; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for specific indications; acceptance of the Company’s product candidates in the marketplace and the successful development, marketing or sale of its products; the Company’s ability to maintain its license agreements; the continued maintenance and growth of the Company’s patent estate and its ability to retain its key employees or maintain the Company’s Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. These risks should not be construed as exhaustive and should be read together with the other cautionary statements contained in such reports. Any forward-looking statement speaks only as of the date on which it was initially made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:

Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 328-4326
Email: mmoyer@lifesciadvisors.co